-Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will stop its cell therapy initiatives and look for a partner to advance its research and clinic-ready programs in this field.
The company said it currently has no active clinical trials utilizing cell therapy technology. It will now focus on other types of treatments, including small molecule drugs, biologics and antibody-drug conjugates.
Takeda has spent years working on cell therapies, including experimental treatments that use modified immune cells to target cancer. The company, however, is now redirecting its investments toward areas where it can deliver innovative medicines to patients faster and at greater scale.
The drugmaker said it expects to recognize an impairment loss of about 58.0 billion Japanese yen ($395.47 million) associated with the gamma delta T-cell therapy platform in the second quarter of fiscal year 2025. However, most of that loss had already been factored into its full-year forecast announced in May.
($1 = 146.6600 yen)
(Reporting by Kamal Choudhury in Bengaluru; Editing by Jane Merriman and Shilpi Majumdar)
Comments